系统性硬化症患者淋巴细胞中共抑制性受体PD-1、TIGIT和TIM-3表达增加及调控活性改变
本研究采用16色流式细胞术检测系统性硬化症(SSc)患者外周血淋巴细胞亚群中共抑制性受体(co-IR)PD-1、TIGIT、TIM-3和LAG-3的表达,并通过体外阻断实验和数学模型分析其功能。结果发现SSc患者特定T细胞亚群中PD-1和TIGIT表达增加且共表达,自然杀伤细胞中TIM-3表达增加;阻断TIGIT和TIM-3(而非PD-1)未能逆转SSc患者受抑的细胞因子产生,提示T细胞耗竭增强。抗TIM-3处理的PBMC培养上清可改变SSc成纤维细胞的基因表达谱。
要点
- SSc患者特定T细胞亚群中PD-1和TIGIT表达增加并共表达,NK细胞中TIM-3表达增加。
- 阻断TIGIT和TIM-3(而非PD-1)未能逆转SSc患者受抑的细胞因子产生,提示T细胞耗竭增强。
- 抗TIM-3处理的PBMC培养上清可改变SSc成纤维细胞的基因表达谱。
核心结论
- SSc淋巴细胞中共抑制性受体表达改变和调控能力变化可能通过调节炎症和/或纤维化部位免疫细胞与成纤维细胞间的细胞因子介导的交互作用参与疾病病理生理。
研究设计与样本
- 研究纳入SSc患者和健康对照,采用16色流式细胞术分析外周血免疫细胞亚群中共抑制性受体表达水平。
- 通过体外刺激SSc和健康对照外周血单个核细胞(PBMC)并在共抑制性受体阻断抗体存在下检测细胞因子产生以确定其功能作用。
- 将刺激后PBMC培养上清加入SSc成纤维细胞,检测其对成纤维细胞基因表达的影响,并采用数学模型揭示SSc患者与健康对照间共抑制性受体功能差异。
主要发现
- 与健康对照相比,SSc患者特定T细胞亚群中PD-1和TIGIT水平增加,且二者共表达。
- SSc患者自然杀伤细胞中TIM-3水平增加。
- PD-1、TIGIT和TIM-3抗体阻断揭示了各共抑制性受体在调节激活诱导的T细胞细胞因子产生中的患者特异性作用。
- 与健康受试者不同,阻断TIGIT和TIM-3(而非PD-1)未能逆转SSc患者中受抑的细胞因子产生,表明SSc患者存在增强的T细胞耗竭。
- 抗TIM-3处理的PBMC培养上清中分泌的细胞因子明显改变了SSc成纤维细胞的基因表达谱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune dysfunction is an important component of the disease process underlying systemic sclerosis (SSc), but the mechanisms contributing to altered immune cell function in SSc remain poorly defined. This study was undertaken to measure the expression and function of the coinhibitory receptors (co-IRs) programmed cell death 1 (PD-1), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin domain 3 (TIM-3), and lymphocyte activation gene 3 (LAG-3) in lymphocyte subsets from the peripheral blood of patients with SSc. METHODS: Co-IR expression levels on subsets of immune cells were analyzed using a 16-color flow cytometry panel. The functional role of co-IRs was determined by measuring cytokine production after in vitro stimulation of SSc and healthy control peripheral blood mononuclear cells (PBMCs) in the presence of co-IR-blocking antibodies. Supernatants from cultures of stimulated PBMCs were added to SSc fibroblasts, and their impact on fibroblast gene expression was measured. Mathematical modeling was used to reveal differences between co-IR functions in SSc patients and healthy controls. RESULTS: Levels of the co-IRs PD-1 and TIGIT were increased, and each was coexpressed, in distinct T cell subsets from SSc patients compared to healthy controls. Levels of TIM-3 were increased in SSc natural killer cells. PD-1, TIGIT, and TIM-3 antibody blockade revealed patient-specific roles of each of these co-IRs in modulating activation-induced T cell cytokine production. In contrast to healthy subjects, blockade of TIGIT and TIM-3, but not PD-1, failed to reverse inhibited cytokine production in SSc patients, indicating that enhanced T cell exhaustion is present in SSc. Finally, cytokines secreted in anti-TIM-3-treated PBMC cultures distinctly changed the gene expression profile in SSc fibroblasts. CONCLUSION: The altered expression and regulatory capacity of co-IRs in SSc lymphocytes may contribute to disease pathophysiology by modulating the cytokine-mediated cross-talk of immune cells and fibroblasts at sites of inflammation and/or fibrosis.
引用
- Fleury M, Belkina AC, Proctor EA, et al. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol. 2018. PMID: 29245183. doi:10.1002/art.40399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。